PDF(Pubmed)
Abstract：
To explore the condition of fellow eyes of patients with macular neovascularization Type 3 (MNV3) and to verify whether the retinal-choroidal anastomosis (RCA) develops equally in all MNV types.
The contralateral eyes of 94 patients with MNV3, 96 patients with MNV1, and 96 patients with MNV2 were included. Multimodal imaging was performed. The MNV3 stage including the development of fibrosis and RCA over 24 months was determined.
In the contralateral eyes of patients of the solitary (one lesion) MNV3 group, 32 eyes (42.1%) showed early/intermediate age-related macular degeneration, 25 eyes (33%) showed MNV3, and 11 eyes (14.5%) experienced fibrosis, of which 4 eyes (5.2%) had a RCA, 7 eyes (9.2%) had atrophy after resolved MNV3, and 1 eye (1.3%) developed MNV1. In the multifocal (more than one lesion) MNV3 group, 2 eyes (11.1%) showed early/intermediate age-related macular degeneration, 9 eyes (50%) showed 15 MNV3 lesions, and 4 eyes (22.2%) showed fibrosis, of which 2 eyes (11.1%) manifested with a RCA and 3 eyes (16.7%) showed atrophy after resolved MNV3. The number of eyes with a RCA accounted for 40% of all eyes with fibrosis. The count of simultaneous bilateral multifocal MNV3 was 5 (55.6%). In the MNV1 and MNV2 groups, no eye developed a RCA. The incidence of RCAs in the scarred eyes in MNV3 was significantly higher (P < 0.0001).
Retinal-choroidal anastomosis is an exclusive clinical feature of MNV3. The development of the multifocal MNV3 is usually bilateral and simultaneous. The occurrence of fibrosis in MNV3 has decreased dramatically after the introduction of the antiangiogenic therapy.
The contralateral eyes of 94 patients with MNV3, 96 patients with MNV1, and 96 patients with MNV2 were included. Multimodal imaging was performed. The MNV3 stage including the development of fibrosis and RCA over 24 months was determined.
In the contralateral eyes of patients of the solitary (one lesion) MNV3 group, 32 eyes (42.1%) showed early/intermediate age-related macular degeneration, 25 eyes (33%) showed MNV3, and 11 eyes (14.5%) experienced fibrosis, of which 4 eyes (5.2%) had a RCA, 7 eyes (9.2%) had atrophy after resolved MNV3, and 1 eye (1.3%) developed MNV1. In the multifocal (more than one lesion) MNV3 group, 2 eyes (11.1%) showed early/intermediate age-related macular degeneration, 9 eyes (50%) showed 15 MNV3 lesions, and 4 eyes (22.2%) showed fibrosis, of which 2 eyes (11.1%) manifested with a RCA and 3 eyes (16.7%) showed atrophy after resolved MNV3. The number of eyes with a RCA accounted for 40% of all eyes with fibrosis. The count of simultaneous bilateral multifocal MNV3 was 5 (55.6%). In the MNV1 and MNV2 groups, no eye developed a RCA. The incidence of RCAs in the scarred eyes in MNV3 was significantly higher (P < 0.0001).
Retinal-choroidal anastomosis is an exclusive clinical feature of MNV3. The development of the multifocal MNV3 is usually bilateral and simultaneous. The occurrence of fibrosis in MNV3 has decreased dramatically after the introduction of the antiangiogenic therapy.
摘要：
探讨黄斑新生血管3型（MNV3）患者的双眼状况，并验证所有MNV类型的视网膜-脉络膜吻合术（RCA）是否同等发展。
纳入94例MNV3患者、96例MNV1患者和96例MNV2患者的对侧眼。进行多模态成像。确定了MNV3阶段，包括24个月内纤维化和RCA的发展。
在孤立（一个病变）MNV3组患者的对侧眼中，32眼（42.1%）显示早期/中期年龄相关性黄斑变性，25眼（33%）显示MNV3，11眼（14.5%）出现纤维化，其中4只眼睛（5.2%）有RCA，7只眼睛（9.2％）在MNV3消退后出现萎缩，1只眼睛（1.3％）出现MNV1。在多灶性（一个以上病变）MNV3组中，2眼（11.1％）显示早期/中期年龄相关性黄斑变性，9眼（50％）显示15个MNV3病变，4眼(22.2%)显示纤维化，其中2只眼（11.1％）出现RCA，3只眼（16.7％）在MNV3解决后出现萎缩。具有RCA的眼睛的数目占所有具有纤维化的眼睛的40%。同时双侧多灶性MNV3的计数为5（55.6％）。在MNV1和MNV2组中，没有眼睛出现RCA。MNV3中瘢痕眼的RCAs发生率明显较高（P<0.0001）。
视网膜-脉络膜吻合术是MNV3的唯一临床特征。多焦点MNV3的发展通常是双边的和同时的。在引入抗血管生成疗法之后,MNV3中的纤维化的发生显著减少。
纳入94例MNV3患者、96例MNV1患者和96例MNV2患者的对侧眼。进行多模态成像。确定了MNV3阶段，包括24个月内纤维化和RCA的发展。
在孤立（一个病变）MNV3组患者的对侧眼中，32眼（42.1%）显示早期/中期年龄相关性黄斑变性，25眼（33%）显示MNV3，11眼（14.5%）出现纤维化，其中4只眼睛（5.2%）有RCA，7只眼睛（9.2％）在MNV3消退后出现萎缩，1只眼睛（1.3％）出现MNV1。在多灶性（一个以上病变）MNV3组中，2眼（11.1％）显示早期/中期年龄相关性黄斑变性，9眼（50％）显示15个MNV3病变，4眼(22.2%)显示纤维化，其中2只眼（11.1％）出现RCA，3只眼（16.7％）在MNV3解决后出现萎缩。具有RCA的眼睛的数目占所有具有纤维化的眼睛的40%。同时双侧多灶性MNV3的计数为5（55.6％）。在MNV1和MNV2组中，没有眼睛出现RCA。MNV3中瘢痕眼的RCAs发生率明显较高（P<0.0001）。
视网膜-脉络膜吻合术是MNV3的唯一临床特征。多焦点MNV3的发展通常是双边的和同时的。在引入抗血管生成疗法之后,MNV3中的纤维化的发生显著减少。
